Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report

In the case of our patient, the synergic action of endocrine therapy and chemotherapy plus dual anti-HER2 combination allowed a complete disease control. Therapy should be scheduled by considering the two cancers as individual entities. The approach to breast cancer is changing from being considered...

Descripción completa

Detalles Bibliográficos
Autores principales: Megaro, Giacomina, Rossi, Luigi, Ceddia, Serena, Sinjari, Marsela, Mannino, Adele, Gozzi, Elisa, Cosimati, Antonella, Brandi, Martina, Bitca, Victoria, Toscani, Ilaria, Cimino, Giuseppe, Tomao, Silverio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275194/
https://www.ncbi.nlm.nih.gov/pubmed/32547382
http://dx.doi.org/10.1159/000507433
_version_ 1783542736423485440
author Megaro, Giacomina
Rossi, Luigi
Ceddia, Serena
Sinjari, Marsela
Mannino, Adele
Gozzi, Elisa
Cosimati, Antonella
Brandi, Martina
Bitca, Victoria
Toscani, Ilaria
Cimino, Giuseppe
Tomao, Silverio
author_facet Megaro, Giacomina
Rossi, Luigi
Ceddia, Serena
Sinjari, Marsela
Mannino, Adele
Gozzi, Elisa
Cosimati, Antonella
Brandi, Martina
Bitca, Victoria
Toscani, Ilaria
Cimino, Giuseppe
Tomao, Silverio
author_sort Megaro, Giacomina
collection PubMed
description In the case of our patient, the synergic action of endocrine therapy and chemotherapy plus dual anti-HER2 combination allowed a complete disease control. Therapy should be scheduled by considering the two cancers as individual entities. The approach to breast cancer is changing from being considered a singular disease to a multiform one, according to current research focused on biological markers such as HER2, ERs, and PRs, with important implications in clinical, prognostic, and therapeutic features.
format Online
Article
Text
id pubmed-7275194
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-72751942020-06-15 Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report Megaro, Giacomina Rossi, Luigi Ceddia, Serena Sinjari, Marsela Mannino, Adele Gozzi, Elisa Cosimati, Antonella Brandi, Martina Bitca, Victoria Toscani, Ilaria Cimino, Giuseppe Tomao, Silverio Case Rep Oncol Case Report In the case of our patient, the synergic action of endocrine therapy and chemotherapy plus dual anti-HER2 combination allowed a complete disease control. Therapy should be scheduled by considering the two cancers as individual entities. The approach to breast cancer is changing from being considered a singular disease to a multiform one, according to current research focused on biological markers such as HER2, ERs, and PRs, with important implications in clinical, prognostic, and therapeutic features. S. Karger AG 2020-05-13 /pmc/articles/PMC7275194/ /pubmed/32547382 http://dx.doi.org/10.1159/000507433 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Megaro, Giacomina
Rossi, Luigi
Ceddia, Serena
Sinjari, Marsela
Mannino, Adele
Gozzi, Elisa
Cosimati, Antonella
Brandi, Martina
Bitca, Victoria
Toscani, Ilaria
Cimino, Giuseppe
Tomao, Silverio
Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report
title Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report
title_full Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report
title_fullStr Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report
title_full_unstemmed Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report
title_short Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report
title_sort synchronous and metachronous metastatic breast cancer, with different histology and opposite immunophenotype, treated with combination of chemotherapy, anti-her2, and endocrine therapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275194/
https://www.ncbi.nlm.nih.gov/pubmed/32547382
http://dx.doi.org/10.1159/000507433
work_keys_str_mv AT megarogiacomina synchronousandmetachronousmetastaticbreastcancerwithdifferenthistologyandoppositeimmunophenotypetreatedwithcombinationofchemotherapyantiher2andendocrinetherapyacasereport
AT rossiluigi synchronousandmetachronousmetastaticbreastcancerwithdifferenthistologyandoppositeimmunophenotypetreatedwithcombinationofchemotherapyantiher2andendocrinetherapyacasereport
AT ceddiaserena synchronousandmetachronousmetastaticbreastcancerwithdifferenthistologyandoppositeimmunophenotypetreatedwithcombinationofchemotherapyantiher2andendocrinetherapyacasereport
AT sinjarimarsela synchronousandmetachronousmetastaticbreastcancerwithdifferenthistologyandoppositeimmunophenotypetreatedwithcombinationofchemotherapyantiher2andendocrinetherapyacasereport
AT manninoadele synchronousandmetachronousmetastaticbreastcancerwithdifferenthistologyandoppositeimmunophenotypetreatedwithcombinationofchemotherapyantiher2andendocrinetherapyacasereport
AT gozzielisa synchronousandmetachronousmetastaticbreastcancerwithdifferenthistologyandoppositeimmunophenotypetreatedwithcombinationofchemotherapyantiher2andendocrinetherapyacasereport
AT cosimatiantonella synchronousandmetachronousmetastaticbreastcancerwithdifferenthistologyandoppositeimmunophenotypetreatedwithcombinationofchemotherapyantiher2andendocrinetherapyacasereport
AT brandimartina synchronousandmetachronousmetastaticbreastcancerwithdifferenthistologyandoppositeimmunophenotypetreatedwithcombinationofchemotherapyantiher2andendocrinetherapyacasereport
AT bitcavictoria synchronousandmetachronousmetastaticbreastcancerwithdifferenthistologyandoppositeimmunophenotypetreatedwithcombinationofchemotherapyantiher2andendocrinetherapyacasereport
AT toscaniilaria synchronousandmetachronousmetastaticbreastcancerwithdifferenthistologyandoppositeimmunophenotypetreatedwithcombinationofchemotherapyantiher2andendocrinetherapyacasereport
AT ciminogiuseppe synchronousandmetachronousmetastaticbreastcancerwithdifferenthistologyandoppositeimmunophenotypetreatedwithcombinationofchemotherapyantiher2andendocrinetherapyacasereport
AT tomaosilverio synchronousandmetachronousmetastaticbreastcancerwithdifferenthistologyandoppositeimmunophenotypetreatedwithcombinationofchemotherapyantiher2andendocrinetherapyacasereport

Ejemplares similares